---
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285269661.md"
description: "Avalo Therapeutics shares are trading higher after the company announced the LOTUS trial successfully met its primary endpoint at both doses studied. The company announced an offering."
datetime: "2026-05-05T21:10:26.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285269661.md)
  - [en](https://longbridge.com/en/news/285269661.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285269661.md)
---

# 

Avalo Therapeutics shares are trading higher after the company announced the LOTUS trial successfully met its primary endpoint at both doses studied. The company announced an offering.

### Related Stocks

- [AVTX.US](https://longbridge.com/en/quote/AVTX.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [BMED.US](https://longbridge.com/en/quote/BMED.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [TMED.US](https://longbridge.com/en/quote/TMED.US.md)

## Related News & Research

- [These Analysts Revise Their Forecasts On Avalo Therapeutics After Q1 Results](https://longbridge.com/en/news/286424446.md)
- [Avalo Therapeutics Urges Investors to Heed Form 10-Q Risk Factors Amid Ongoing Uncertainty](https://longbridge.com/en/news/286366040.md)
- [Avalo Therapeutics Q1 net loss widens on increased R&D spend](https://longbridge.com/en/news/286249018.md)
- [Tiziana Announces New Positive Clinical Data For Intranasal Foralumab In Non-Active Secondary Progressive Multiple Sclerosis](https://longbridge.com/en/news/286899753.md)
- [BUZZ-Street View: Regeneron's melanoma trial setback raises bigger-picture questions](https://longbridge.com/en/news/286769076.md)